Large Pharma Transformations
Large pharma organizations face a unique challenge: transforming at scale without disrupting commercial operations or regulatory compliance. Dr. Kurr has led enterprise-wide transformation programs at Boehringer Ingelheim and Novartis, redesigning operating models, building global service organizations, and implementing digital workflows across dozens of markets simultaneously. His approach - structure follows process follows strategy - ensures that reorganizations create real operational improvement, not just new reporting lines. At Boehringer Ingelheim, this approach delivered a tenfold organization expansion and full global coverage in four years.
Specialty Pharma Scale-Up
Specialty pharma companies operate in a different paradigm - smaller patient populations, complex distribution, and specialized HCP engagement. Scaling commercial operations in specialty pharma requires operating models that are lean but sophisticated: targeted go-to-market strategies, efficient content supply chains, and compliance frameworks adapted to niche therapeutic areas. Dr. Kurr helps specialty pharma organizations build scalable commercial infrastructure without the overhead of large pharma organizational complexity.
Emerging Biotech Commercialization
For emerging biotech companies transitioning from R&D to commercial stage, the leap to market readiness is one of the most critical - and most frequently mismanaged - milestones. Dr. Kurr's fractional C-level model is purpose-built for this transition: providing experienced commercial leadership without the full-time cost. At Lemna Bio, he leads commercial strategy and partnership development for a computational drug design company, bringing the same rigor he applied at Boehringer Ingelheim to a pre-commercial biotech context. This includes market shaping, commercial partnership structuring, go-to-market planning, and organizational readiness.
Go-to-Market Redesign
Traditional pharma go-to-market models - field-force-centric, territory-based, and siloed by function - are no longer fit for purpose. Modern go-to-market requires omnichannel orchestration, data-driven targeting, and integrated commercial-medical engagement. Dr. Kurr built Boehringer Ingelheim's go-to-market services organization from scratch, including a Digital Content Factory, Creative Factory, and Global Services Delivery Unit. His strategic partnership with Indegene transformed go-to-market operations across global markets, enabling more agile, data-driven, omnichannel physician and patient engagement.